PMCB

PharmaCyte Biotech, Inc. PMCB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jul 31

Net income

$-5.08M

Quarter to Jul 31

Top Institutional Holders

as of Q2 2026
$586.2K total
CITADEL ADVISORS LLC
$218.2K-21.2%
GEODE CAPITAL MANAGEMENT, LLC
$95.7K-36.5%
VANGUARD CAPITAL MANAGEMENT LLC
$43.7K+10.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$34.5KNew
RENAISSANCE TECHNOLOGIES LLC
$29.3K-32.8%
XTX Topco Ltd
$26.3K-34.7%
NORTHERN TRUST CORP
$25.1K-8.4%
JANE STREET GROUP, LLC
$23.1K+160.7%
Schonfeld Strategic Advisors LLC
$20.7K-0.3%
VANGUARD FIDUCIARY TRUST CO
$18.1K0.0%
EQUITEC PROPRIETARY MARKETS, LLC
$17.1K0.0%
COMMONWEALTH EQUITY SERVICES, LLC
$15.6K+96.4%
HRT FINANCIAL LP
$11.0K-37.5%
Tower Research Capital LLC (TRC)
$3.8K0.0%
UBS Group AG
$3.2K-8.3%
GROUP ONE TRADING, L.P.
$385-72.0%
OSAIC HOLDINGS, INC.
$232+0.3%
BARCLAYS PLC
$148New
Sachetta, LLC
$110.0%
SBI Securities Co., Ltd.
$5+100.0%
BFSG, LLC
$40.0%
CoreCap Advisors, LLC
$3New
FINANCIAL CONSULATE, INC
$20.0%
NewEdge Advisors, LLC
$2New
CALDWELL SUTTER CAPITAL, INC.
$20.0%
See all 32 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

ROIC

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PMCB

Earnings Per Share

13fpro.ai/company/PMCB

Loading ratio trend…

PMCB key financials by period

Reported revenue, net income and operating margin by fiscal year, from PharmaCyte Biotech, Inc.'s annual filings on SEC EDGAR.

PharmaCyte Biotech, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2013$12.2K$-1.6M—
FY 2012$66.6K$-1.9M—
FY 2011$126.0K$-1.4M—
Source: PMCB filings on SEC EDGAR →

PMCB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About PharmaCyte Biotech, Inc. (PMCB): stock profile, AI score and financials

PharmaCyte Biotech, Inc. (PMCB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PMCB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Top institutional holders of PMCB by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PMCB trades on the Nasdaq exchange and files with the SEC under CIK 1157075. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMCB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PharmaCyte Biotech, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1157075 →